biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > RNAi

<< Previous

Bullboard Posts

Next >>

Comment by DeadMonkeyon May 04, 2023 10:05am

81 Views

Post# 35429770

RE:RE:RE:RNAi

A non-human primate study was conducted under MD and XB3 was shown to work in monkeys - it crossed the bloodbrainbarrier and penetrated the lymph system.it works. why do you think prothena's drug is working? keep a close eye on the parts of the bms pipeline they got through celgene acquisition. shareholders have been duped.this shareholder thinks DR and BOD should be in jail.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale